These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31247277)

  • 1. Transscleral sustained ranibizumab delivery using an episcleral implantable device: Suppression of laser-induced choroidal neovascularization in rats.
    Nagai N; Nezhad ZK; Daigaku R; Saijo S; Song Y; Terata K; Hoshi A; Nishizawa M; Nakazawa T; Kaji H; Abe T
    Int J Pharm; 2019 Aug; 567():118458. PubMed ID: 31247277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Release of ranibizumab using a porous poly(dimethylsiloxane) capsule suppressed laser-induced choroidal neovascularization via the transscleral route.
    Nagai N; Daigaku R; Motoyama R; Kaji H; Abe T
    J Mater Sci Mater Med; 2022 Dec; 34(1):5. PubMed ID: 36586040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transscleral sustained vasohibin-1 delivery by a novel device suppressed experimentally-induced choroidal neovascularization.
    Onami H; Nagai N; Kaji H; Nishizawa M; Sato Y; Osumi N; Nakazawa T; Abe T
    PLoS One; 2013; 8(3):e58580. PubMed ID: 23472209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo Efficacy of an Injectable Microsphere-Hydrogel Ocular Drug Delivery System.
    Osswald CR; Guthrie MJ; Avila A; Valio JA; Mieler WF; Kang-Mieler JJ
    Curr Eye Res; 2017 Sep; 42(9):1293-1301. PubMed ID: 28557571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo and in vitro sustained release of ranibizumab from a nanoporous thin-film device.
    Lance KD; Bernards DA; Ciaccio NA; Good SD; Mendes TS; Kudisch M; Chan E; Ishikiriyama M; Bhisitkul RB; Desai TA
    Drug Deliv Transl Res; 2016 Dec; 6(6):771-780. PubMed ID: 27178165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A scalable controlled-release device for transscleral drug delivery to the retina.
    Kawashima T; Nagai N; Kaji H; Kumasaka N; Onami H; Ishikawa Y; Osumi N; Nishizawa M; Abe T
    Biomaterials; 2011 Mar; 32(7):1950-6. PubMed ID: 21112628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A polymeric device for controlled transscleral multi-drug delivery to the posterior segment of the eye.
    Nagai N; Kaji H; Onami H; Ishikawa Y; Nishizawa M; Osumi N; Nakazawa T; Abe T
    Acta Biomater; 2014 Feb; 10(2):680-7. PubMed ID: 24239899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization.
    Kachi I; Yasukawa T; Kato A; Takase N; Morita H; Kubota A; Hirano Y; Uemura A; Ogura Y
    Jpn J Ophthalmol; 2016 May; 60(3):179-86. PubMed ID: 26919844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue therapy with intravitreal aflibercept for choroidal neovascularization secondary to choroidal osteoma non-responder to intravitreal bevacizumab and ranibizumab.
    Saitta A; Nicolai M; Neri P; Reibaldi M; Giovannini A; Mariotti C
    Int Ophthalmol; 2015 Jun; 35(3):441-4. PubMed ID: 25761547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration.
    Ladas ID; Chatziralli IP; Kotsolis AI; Douvali M; Georgalas I; Theodossiadis PG; Rouvas AA
    Ophthalmologica; 2012; 228(2):93-101. PubMed ID: 22571933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab.
    Elsaid N; Jackson TL; Elsaid Z; Alqathama A; Somavarapu S
    Mol Pharm; 2016 Sep; 13(9):2923-40. PubMed ID: 27286558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal Administration of Ranibizumab and Bevacizumab for Choroidal Neovascularization Secondary to Ocular Toxocariasis: A Case Report.
    Yoon DY; Woo SJ
    Ocul Immunol Inflamm; 2018; 26(4):639-641. PubMed ID: 27775459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal ranibizumab for choroidal neovascularization in a patient with angioid streaks and multiple evanescent white dots.
    Pece A; Allegrini D; Kontadakis S; Querques G; Rossetti L
    BMC Ophthalmol; 2016 Jul; 16():122. PubMed ID: 27457484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.
    Robinson MR; Baffi J; Yuan P; Sung C; Byrnes G; Cox TA; Csaky KG
    Exp Eye Res; 2002 Feb; 74(2):309-17. PubMed ID: 11950241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transscleral Controlled Delivery of Geranylgeranylaceton Using a Polymeric Device Protects Rat Retina Against Light Injury.
    Nagai N; Kaji H; Nishizawa M; Nakazawa T; Abe T
    Adv Exp Med Biol; 2016; 854():471-7. PubMed ID: 26427448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey.
    Husain D; Kim I; Gauthier D; Lane AM; Tsilimbaris MK; Ezra E; Connolly EJ; Michaud N; Gragoudas ES; O'Neill CA; Beyer JC; Miller JW
    Arch Ophthalmol; 2005 Apr; 123(4):509-16. PubMed ID: 15824225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab.
    Ladaique M; Dirani A; Ambresin A
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):542-7. PubMed ID: 25902117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choroidal Thickness Changes After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
    Minnella AM; Federici M; Falsini B; Barbano L; Gambini G; Lanza A; Caporossi A; Savastano MC
    BioDrugs; 2016 Aug; 30(4):353-9. PubMed ID: 27189458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416.
    Honda M; Asai T; Umemoto T; Araki Y; Oku N; Tanaka M
    Arch Ophthalmol; 2011 Mar; 129(3):317-21. PubMed ID: 21402988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A drug refillable device for transscleral sustained drug delivery to the retina.
    Nagai N; Saijo S; Song Y; Kaji H; Abe T
    Eur J Pharm Biopharm; 2019 Mar; 136():184-191. PubMed ID: 30690065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.